Jacobio Pharma to Present Data of KRAS G12C Inhibitor Glecirasib in ...
Jacobio Pharma to present clinical results of KRAS G12C inhibitor glecirasib at 2024 ASCO GI. Glecirasib, granted breakthrough therapy designation for pancreatic cancer, shows promise in ongoing trials for solid tumors with KRAS G12C mutation, aiming to expedite treatment access.
Reference News
Jacobio Pharma to Present Data of KRAS G12C Inhibitor Glecirasib in ...
Jacobio Pharma to present clinical results of KRAS G12C inhibitor glecirasib at 2024 ASCO GI. Glecirasib, granted breakthrough therapy designation for pancreatic cancer, shows promise in ongoing trials for solid tumors with KRAS G12C mutation, aiming to expedite treatment access.